Pharnext and the Charcot–Marie–Tooth Association enter Biomarker Research Collaboration
Pharnext appoints Adrian Hepner, MD, PhD as Chief Medical Officer
Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of CMT1A
Pharnext Presents a Business Update Webcast on May 20th, 2020
Pharnext Reports Financial Results for Year-End 2019
Pharnext and the UHI Méditerranée Infection announce a joint effort to evaluate repurposed drugs for potential use against the COVID-19 Virus
Pharnext will hold a Business Overview Webcast on May 20th, 2020
Pharnext announces the appointment of David Horn Solomon as Chief Executive Officer
Pharnext to organizes a Webcast to take stock of Pharnext, clinical development and research on April 23, 2020 (only avaible in French)
Pharnext announces identification of a large set of frequently prescribed drugs to be repurposed for fighting COVID-19, using its Pleotherapy™ platform
PXT3003 for the treatment of CMT1A granted Promising Innovative Medicine (PIM) Designation by UK MHRA
Pharnext raises € 7.7 million in a private placement
PXT3003: Encouraging Data from Open-Label Phase 3 Extension Study in CMT1A
Pharnext establishes an equity line facility with Kepler Cheuvreux
Pharnext announces 2019 half-year results
Pharnext and Galapagos successfully achieved their research and development collaboration
Pharnext provides U.S. regulatory update on PLEODRUG PXT3003 in CMT1A
Video of Peter Collum, new Chief Financial Officer and Chief Business Officer
Pharnext Announces the Apppointment of Peter Collum as Chief Financial Officer and Chief Business Officer
Pharnext confirms its eligibility to the French SME equity savings plan "PEA-PME" (only available in French)
Pharnext reports financial results for Year-End 2018
Pharnext to reinforce equity capital by conversion of convertibles bonds
Pharnext to host a KOL investors event focused on CMT in Paris (only availbable in French)
PXT3003: FDA Fast Track designation for the treatment of CMT1A
Pharnext raises €15 million without discount
PXT3003: Early therapeutic effects in a transgenic rat model of CMT1A
Susanne Dorn and Serge Fitoussi appointed as Chief Regulatory Officer and Chief Medical Officer
Pharnext to present at BMO 2018 Prescriptions for Success Healthcare Conference
Page 1 of 4
